Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $78.3 million.

  • United Therapeutics' Other Accumulated Expenses fell 224.72% to $78.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.3 million, marking a year-over-year decrease of 224.72%. This contributed to the annual value of $93.6 million for FY2024, which is 3183.1% up from last year.
  • United Therapeutics' Other Accumulated Expenses amounted to $78.3 million in Q3 2025, which was down 224.72% from $95.1 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Other Accumulated Expenses registered a high of $154.5 million during Q1 2025, and its lowest value of $24.8 million during Q2 2021.
  • For the 5-year period, United Therapeutics' Other Accumulated Expenses averaged around $63.2 million, with its median value being $60.8 million (2022).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 4758.06% in 2021, then soared by 22720.21% in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' Other Accumulated Expenses stood at $28.4 million in 2021, then grew by 14.44% to $32.5 million in 2022, then soared by 118.46% to $71.0 million in 2023, then soared by 31.83% to $93.6 million in 2024, then dropped by 16.35% to $78.3 million in 2025.
  • Its Other Accumulated Expenses stands at $78.3 million for Q3 2025, versus $95.1 million for Q2 2025 and $154.5 million for Q1 2025.